QUICK ANSWER · AEO / GEO
Also known as cibinetide, an investigational peptide studied in inflammatory and neuropathy contexts; clinical evidence remains indication-specific.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- long-term safety, immunogenicity and rare adverse effects
- whether biomarker changes translate into durable patient-important outcomes
- effective and safe use in larger, diverse populations
- current development status and whether confirmatory trials will occur
- quality and identity of products marketed under ARA-290, cibinetide or pHBSP names
- current marketing-authorisation status in Thailand and national EU jurisdictions
What limits these conclusions?
- The clinical program is based mainly on small, short studies involving related research teams and sponsor participation. Several outcomes were exploratory, subgroup-based or surrogate biomarkers. The diabetic macular edema study was open-label and uncontrolled. No verified Phase 3 confirmatory trial or marketing approval establishes clinical benefit.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://precision.fda.gov/uniisearch/srs/unii/9w5677jkda
- https://www.fda.gov/media/94155/download
- https://www.fda.gov/media/94164/download
- https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1721
- https://clinicaltrials.gov/study/NCT02039687
- https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003016-45/results
- https://pubmed.ncbi.nlm.nih.gov/23168581/
- https://pubmed.ncbi.nlm.nih.gov/24136731/
- https://pubmed.ncbi.nlm.nih.gov/28475703/
- https://pubmed.ncbi.nlm.nih.gov/25387363/
- https://pubmed.ncbi.nlm.nih.gov/32674280/
- https://pubmed.ncbi.nlm.nih.gov/29026145/
- https://pubmed.ncbi.nlm.nih.gov/32345869/
- https://products.mhra.gov.uk/
- https://www.ema.europa.eu/en/medicines/download-medicine-data
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
FAQ · ANSWER ENGINE
Frequently asked questions
What is ARA-290 (Cibinetide)?
ARA-290 (Cibinetide) is described pharmacologically as Investigational erythropoietin-derived tissue-protective peptide. Also known as cibinetide, an investigational peptide studied in inflammatory and neuropathy contexts; clinical evidence remains indication-specific.
Does ARA-290 (Cibinetide) have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is ARA-290 (Cibinetide) approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.